Intellia Therapeutics has announced that its CRISPR gene-editing therapy for a rare swelling disorder has successfully met all primary endpoints in a pivotal late-stage clinical trial. This achievement represents a significant milestone for the gene-editing field, and the company is now advancing the regulatory approval process with the U.S. Food and Drug Administration (FDA).
The therapy utilizes Nobel Prize-winning CRISPR technology to edit DNA and turn off the gene responsible for producing a specific peptide. In patients with hereditary angioedema, overactivity of this peptide leads to recurrent and potentially life-threatening episodes of swelling throughout the body.
Administered as a one-time treatment via a several-hour intravenous infusion, the therapy performs in vivo gene editing directly within the liver.
Trial data demonstrated that the single-dose therapy reduced the frequency of disease attacks by 87% compared to a placebo group, successfully achieving the study's main goal. Six months post-treatment, 62% of patients experienced no attacks and did not require any additional medications.
The company reported that the therapy's overall safety and tolerability profile was favorable, with the most common side effects being infusion-related reactions, headache, and fatigue. The safety data was closely watched by industry analysts, particularly following a previous case of a patient death due to liver toxicity in another of Intellia's investigational therapy trials.
John Leonard, CEO of Intellia Therapeutics, stated: "Reflecting on the origins of CRISPR technology, it has progressed from a fundamental scientific breakthrough to clinical application in just 12 years. While the industry has celebrated incremental successes, this is the world's first in vivo CRISPR gene-editing therapy to report positive Phase 3 clinical data, achieving precise correction of the disease-causing gene."
Currently, the only FDA-approved CRISPR-based medicine, Casgevy, developed by Vertex Pharmaceuticals, is an ex vivo therapy. This process involves extracting a patient's blood cells, editing them outside the body, and then reinfusing them.
In contrast, Intellia's therapy edits genes in vivo, directly inside the body, representing a fundamentally different technological approach.
Intellia has initiated a rolling submission of its marketing application to the FDA and expects to complete the submission in the second half of this year. If approved, the therapy could be commercially launched in the United States in the first half of 2027.
The therapy, with the generic name lonvoguran ziclumeran, will compete with more than a dozen long-term prophylactic treatments for hereditary angioedema (HAE) upon approval.
Although a one-time curative therapy is highly attractive, the commercial performance of gene therapies has historically been mixed. For example, BioMarin Pharmaceutical voluntarily withdrew its gene therapy for hemophilia A from the market due to weak sales.
Leonard highlighted a fundamental difference between the two products: BioMarin's therapy faced market skepticism regarding the durability of its long-term efficacy, whereas Intellia's long-term follow-up data, spanning nearly six years, has not shown a single case of waning treatment effect.
Despite the excellent trial results, he cautiously avoided labeling the therapy a "functional cure." "This is a turning point not only for the treatment of this rare disease but also for the field of in vivo CRISPR gene editing. A single genetic modification can deliver long-term, stable therapeutic benefit." "To date, across this trial and other pipeline programs, we have not observed any instances of reduced editing efficiency or disease symptom recurrence in patients, which is a profoundly breakthrough result."
Comments